Lung Stent Market By Product Type (Metallic Stents, Silicone Stents, Hybrid Stents, Bioresorbable Stents); By Indication (Lung Cancer, COPD, Tracheobronchial Strictures, Post-Surgical Cases); By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Diagnostic Centers); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Lung Stent Market is projected to grow from USD 510 million in 2024 to nearly USD 800 million by 2030 at a 6.8% CAGR, driven by rising lung cancer, COPD, airway obstruction treatment, interventional pulmonology, and advanced metallic and silicone stent technologies, as per Strategic Market Research.

 

Lung stents are medical implants used to maintain airway patency in patients suffering from conditions such as lung cancer, chronic obstructive pulmonary disease (COPD), tracheobronchial strictures, and post-surgical airway collapse. By preventing airway obstruction and restoring airflow, they play a vital role in improving survival and quality of life, particularly in advanced-stage patients where surgical interventions are limited.

 

The market’s relevance is expanding due to the rising global burden of lung cancer and COPD, both of which remain leading causes of morbidity and mortality. Asia-Pacific is seeing a particularly sharp rise, linked to smoking prevalence and air pollution, while North America and Europe face a surge in airway complications associated with aging populations.

 

Technology is reshaping this field. A clear shift is occurring from traditional metallic stents to advanced drug-eluting and bioresorbable options designed to reduce risks such as stent migration or restenosis. Digital imaging and robotic-assisted bronchoscopy are also improving precision in stent placement, widening adoption in tertiary care centers .

 

Policy frameworks are supporting this growth as well. Regulatory bodies such as the U.S. FDA and the European Medicines Agency have cleared several new designs in recent years, opening pathways for faster commercialization. In developing countries, public health reforms and better reimbursement coverage for lung cancer care are indirectly driving higher stent adoption.

 

The stakeholder base is diverse. Original equipment manufacturers continue to focus on innovation and expanding product portfolios. Hospitals and specialty clinics are building out pulmonology and thoracic surgery services. Public agencies are setting treatment mandates for advanced cancer care, while private investors see the lung stent market as a resilient niche tied to chronic disease trends.

 

In truth, lung stents are no longer just a stopgap measure for late-stage patients. As innovation accelerates, they are becoming a key element of precision respiratory care — bridging oncology, pulmonology, and interventional medicine in ways that were unthinkable a decade ago.

 

Comprehensive Market Snapshot

• The Global Lung Stent Market will witness a steady CAGR of 6.8%, valued at USD 510 million in 2024 and expected to reach nearly USD 800 million by 2030.

• The USA Lung Stent Market, accounting for 36% of the global revenue, was valued at approximately USD 183.6 million in 2024 and is projected to expand at a CAGR of 5.9%, reaching nearly USD 258.9 million by 2030.

• The Europe Lung Stent Market, representing 24% of the global share, stood at around USD 122.4 million in 2024 and is anticipated to grow at a CAGR of 4.7%, reaching approximately USD 161.3 million by 2030.

• The APAC Lung Stent Market, holding a 12% share of the global market, was valued at nearly USD 61.2 million in 2024 and is projected to grow at the fastest CAGR of 8.3%, reaching close to USD 98.7 million by 2030.

 

Market Segmentation Insights

By Product Type

• Metallic Stents held the largest market share of approximately 42% in 2024, reflecting strong adoption in malignant airway obstruction and severe tracheal compression cases, with an estimated market value of around USD 214.2 million.

• Silicone Stents accounted for about 28% share in 2024, translating to an estimated value of approximately USD 142.8 million, supported by their removability and lower risk of tissue ingrowth in benign airway conditions.

• Hybrid Stents captured nearly 18% of the global market in 2024, corresponding to a market value of about USD 91.8 million, driven by their combined strength and biocompatibility advantages.

• Bioresorbable Stents represented roughly 12% share in 2024, valued at approximately USD 61.2 million, and are projected to grow at the fastest CAGR during 2024–2030, supported by innovation in temporary airway scaffolding solutions.

 

By Indication

• Lung Cancer represented the highest application share of approximately 35% in 2024, supported by the high global burden of malignant airway obstruction, corresponding to a market value of around USD 178.5 million.

• COPD accounted for about 30% of the market in 2024, translating to an estimated value of approximately USD 153.0 million, driven by advanced-stage airway collapse management.

• Tracheobronchial Strictures captured nearly 20% share in 2024, with a market value of around USD 102.0 million, supported by post-infectious and benign airway narrowing cases.

• Post-Surgical Cases represented approximately 15% of the global market in 2024, valued at nearly USD 76.5 million, reflecting complications following thoracic and lung surgeries.

 

By End User

• Hospitals dominated usage with around 65% market share in 2024, reflecting concentration of advanced bronchoscopy and interventional pulmonology capabilities, equivalent to approximately USD 331.5 million.

• Specialty Clinics accounted for about 18% of the global market in 2024, translating to an estimated value of around USD 91.8 million, supported by growing urban respiratory centers.

• Ambulatory Surgical Centers (ASCs) captured approximately 10% share in 2024, valued at around USD 51.0 million, and are expected to grow at a notable CAGR during 2024–2030, driven by the shift toward minimally invasive outpatient procedures.

• Diagnostic Centers represented roughly 7% of the market in 2024, corresponding to an estimated value of approximately USD 35.7 million, supported by expanding bronchoscopy-based outpatient diagnostics.

 

Strategic Questions Driving the Next Phase of the Global Lung Stent Market

1. What device types, materials, and airway indications are explicitly included within the Global Lung Stent Market, and which adjacent airway management or thoracic devices fall outside its scope?

2. How does the lung stent market differ structurally from adjacent interventional pulmonology segments such as bronchoscopic ablation, airway valves, tracheostomy tubes, and thoracic surgical implants?

3. What is the current and projected size of the Global Lung Stent Market, and how is revenue distributed across product types such as metallic, silicone, hybrid, and bioresorbable stents?

4. How is revenue allocated between malignant (oncology-driven) and benign airway indications, and how is this mix expected to evolve over time?

5. Which indication groups (lung cancer, COPD-related airway collapse, tracheobronchial strictures, post-surgical complications) account for the largest and fastest-growing revenue pools?

6. Which product segments contribute disproportionately to profitability and margin expansion, particularly in premium hybrid or next-generation coated stents?

7. How does demand differ between emergency airway stabilization and planned interventional procedures, and how does this affect device selection?

8. How are treatment algorithms evolving between temporary, removable, and permanent stent placement strategies?

9. What role do revision rates, stent migration, granulation tissue formation, and replacement frequency play in long-term revenue generation?

10. How are disease prevalence trends—particularly lung cancer and COPD—along with aging demographics shaping global demand patterns?

11. What clinical limitations, training gaps, or complication risks constrain adoption across certain regions or healthcare settings?

12. How do reimbursement frameworks, hospital procurement models, and public healthcare budgets influence revenue realization across regions?

13. How strong is the innovation pipeline in areas such as bioresorbable materials, drug-eluting coatings, anti-migration designs, and patient-specific 3D-printed stents?

14. To what extent will next-generation technologies expand the treated patient pool versus intensify competition within established metallic and silicone segments?

15. How are advancements in bronchoscopy, imaging guidance, and minimally invasive techniques improving placement accuracy and patient outcomes?

16. How could regulatory changes or quality standard upgrades impact time-to-market and competitive positioning for manufacturers?

17. What role will low-cost domestic manufacturers in emerging markets play in price competition and accessibility expansion?

18. How are leading companies aligning their portfolios—through material innovation, physician training programs, and bundled respiratory solutions—to defend or expand market share?

19. Which geographic markets are expected to outperform global growth in the Global Lung Stent Market, and which indication or product segments are driving this outperformance?

20. How should manufacturers, distributors, and investors prioritize product innovation, geographic expansion, and clinical partnerships to maximize long-term value creation in the lung stent ecosystem?

 

Segment-Level Insights and Market Structure - Lung Stent Market

The Lung Stent Market is structured around material technologies, clinical indications, and care delivery settings that reflect how airway obstruction is managed across malignant and benign respiratory conditions. Unlike purely pharmaceutical markets, this segment is deeply procedure-driven, with value influenced not only by device pricing but also by interventional expertise, bronchoscopy infrastructure, and hospital procurement models.

Each segment contributes differently to overall revenue generation, competitive positioning, and long-term growth, shaped by disease severity, patient life expectancy, reversibility of airway narrowing, and regional healthcare access.

 

Product Type Insights

Metallic Stents
Metallic stents, typically composed of stainless steel or nitinol, represent the most established and widely utilized product category. Their high radial strength and self-expanding properties make them particularly suitable for malignant airway obstruction where sustained patency is critical. From a commercial perspective, metallic stents anchor baseline procedural volumes, especially in oncology-driven indications. Their durability and compatibility with minimally invasive bronchoscopic deployment continue to support consistent adoption across tertiary hospitals.

Silicone Stents
Silicone stents serve an important role in benign airway conditions due to their removability and lower risk of tissue ingrowth. These devices are often selected in younger patients or in cases where airway remodeling is expected to improve over time. Although technically more demanding to place compared to self-expanding metallic designs, silicone stents maintain strong relevance in specialized pulmonary centers. Their clinical flexibility sustains steady demand in non-malignant indications.

Hybrid Stents
Hybrid stents combine metallic frameworks with silicone or polymer coverings to balance strength and biocompatibility. This segment is positioned between durability and removability, making it attractive for complex airway strictures. Commercially, hybrid designs are increasingly viewed as premium products due to their engineered features aimed at reducing migration and granulation formation. Their adoption reflects growing physician preference for devices that minimize repeat interventions.

Bioresorbable Stents
Bioresorbable stents represent an innovation-driven segment focused on temporary airway scaffolding. Designed to gradually dissolve after restoring airway patency, these devices aim to reduce long-term complications and eliminate removal procedures. Although still emerging relative to established materials, this category is strategically important due to its potential to redefine treatment algorithms in select benign and pediatric cases. Over the forecast period, bioresorbable solutions are expected to attract research and development investment.

 

Indication Insights

Lung Cancer
Lung cancer remains the dominant clinical driver of lung stent utilization. Airway obstruction is a frequent complication in advanced-stage disease, making stenting a critical palliative intervention. From a market standpoint, oncology-driven demand contributes a substantial portion of procedural revenue, particularly in high-income regions with structured cancer care pathways. The segment benefits from rising global cancer incidence and expanded interventional pulmonology capabilities.

Chronic Obstructive Pulmonary Disease (COPD)
COPD-related airway collapse represents another meaningful source of demand, particularly in aging populations with high smoking prevalence. In advanced stages, structural airway support may be necessary to improve airflow and reduce respiratory distress. While not as procedure-intensive as oncology cases, COPD-driven stenting reflects a steady and growing patient base in both developed and emerging markets.

Tracheobronchial Strictures
Benign strictures arising from infections, prolonged intubation, or inflammatory disorders form a distinct treatment segment. These cases often require carefully selected stents that balance removability with sufficient airway support. This segment is closely tied to hospital procedural expertise and often overlaps with thoracic surgical follow-up care.

Post-Surgical Cases
Post-operative airway complications following lung resections or thoracic procedures create episodic but clinically significant demand. In such cases, stenting is frequently used as a corrective intervention to manage narrowing or collapse. While smaller in volume compared to oncology, this segment underscores the procedural and complication-management nature of the lung stent market.

 

Segment Evolution Perspective

The Lung Stent Market is gradually transitioning from purely material-based competition toward integrated airway management solutions. Established metallic and silicone products continue to anchor procedural volumes, but hybrid and bioresorbable technologies are introducing differentiation based on patient outcomes and complication reduction. At the same time, care delivery is slowly diversifying beyond large hospitals as minimally invasive respiratory procedures gain acceptance in outpatient settings. Over the coming years, value distribution across segments will be shaped by oncology trends, COPD prevalence, technological refinement, and regional access to trained interventional pulmonologists.

 

Market Segmentation And Forecast Scope

The lung stent market is defined across several dimensions that reflect how clinicians and healthcare systems choose devices based on disease type, clinical setting, and geographic availability. Each segmentation highlights how providers balance safety, durability, and patient outcomes when selecting the appropriate stent.

By Product Type
Metallic stents, typically made from stainless steel or nitinol, remain widely used due to their strength and ability to withstand airway compression. However, silicone stents are favored in cases requiring removability and lower risks of granulation tissue formation. Hybrid stents that combine metallic frameworks with silicone coverings are gaining adoption for their balance of strength and biocompatibility. A growing category is bioresorbable stents, designed to dissolve after maintaining airway patency for a defined period, reducing the need for repeat interventions.

 

By Indication
The largest share of demand comes from lung cancer cases, where airway obstruction is a common complication. Chronic obstructive pulmonary disease (COPD) also drives significant use, particularly in advanced stages where airway collapse occurs. Additional indications include tracheobronchial strictures, infections leading to airway narrowing, and post-surgical complications following lung or thoracic procedures. Lung cancer accounts for more than one-third of the market in 2024, reflecting the continuing global cancer burden.

 

By End User
Hospitals dominate usage, particularly tertiary and specialized cancer centers where pulmonologists and thoracic surgeons routinely perform interventional airway procedures. Specialty clinics and ambulatory surgical centers are also becoming important, particularly in urban areas with expanding access to minimally invasive respiratory care. Diagnostic centers with bronchoscopy capabilities are a smaller but growing segment, driven by outpatient procedures and quicker recovery times.

 

By Region
North America remains the largest regional market, driven by high rates of lung cancer diagnosis, robust reimbursement policies, and early adoption of advanced stent designs. Europe closely follows, supported by public healthcare systems and standardized treatment protocols. Asia-Pacific is projected to grow at the fastest pace due to rising respiratory disease prevalence, population size, and government-led investments in cancer care infrastructure. Latin America, the Middle East, and Africa remain underpenetrated but present long-term growth opportunities as healthcare access expands.

 

While this segmentation appears clinical, it’s increasingly commercial as well. Vendors are positioning portfolios not just by material but by integrated treatment solutions — offering bundled devices, imaging tools, and physician training programs. That commercial layering makes stent choice as much about the provider’s strategy as it is about the patient’s condition.

 

Market Trends And Innovation Landscape

The lung stent market is transitioning from a largely mechanical solution to a more integrated, technology-driven space. Innovation is being shaped by material science, drug delivery advances, and the need for patient-specific approaches. Several trends stand out in 2024–2030 that will reshape how stents are designed, implanted, and monitored.

 

One of the most visible shifts is the rise of bioresorbable stents. Unlike permanent metallic or silicone devices, these stents are engineered to maintain airway patency for a fixed period before naturally dissolving. This reduces long-term complications like infection, migration, or granulation tissue buildup. Research groups and medtech startups are actively exploring polymer-based solutions, with some early-stage trials reporting encouraging results for safety and efficacy.

 

Drug-eluting stents are another focal point. These devices incorporate coatings that gradually release anti-inflammatory or anti-proliferative drugs, reducing restenosis and tissue overgrowth — two of the most common complications with conventional stents. Pharmaceutical-device partnerships are expanding, with several pipeline products expected to enter the market by 2027.

 

Digital integration is becoming central as well. Imaging-guided placement using robotic bronchoscopy and AI-assisted navigation platforms is enabling more precise stent deployment. These tools reduce misplacement risks and improve procedural outcomes, especially in complex airway anatomies. In some advanced centers, bronchoscopy suites are already using AI-driven software that maps obstructions in 3D before stent insertion.

 

Another trend is the focus on patient-specific customization. With 3D printing, manufacturers can create stents tailored to individual airway structures. Early case studies show 3D-printed stents reducing complication rates in patients with rare or complex bronchial malformations. While not yet mainstream, this approach is drawing strong interest in academic hospitals and is likely to expand into broader clinical use within this decade.

 

On the commercial side, vendors are differentiating by offering integrated solutions rather than stand-alone products. Some companies bundle stents with bronchoscopy catheters, training programs, and even remote monitoring platforms. This shift reflects a growing realization that success depends not only on the device itself but on the ecosystem supporting its implantation and follow-up.

 

What’s striking is how the market has moved beyond simply keeping airways open. The next generation of lung stents is about minimizing complications, shortening recovery, and aligning with precision oncology. In other words, the market is evolving from reactive to proactive — treating the airway not just as a passageway, but as part of a larger continuum of respiratory care.

 

Competitive Intelligence And Benchmarking

The lung stent market, though niche compared to broader interventional cardiology or oncology devices, features a focused group of companies that compete on innovation, pricing, and clinical trust. The competitive environment is shaped less by volume and more by product differentiation, regulatory approvals, and strategic partnerships with leading hospitals.

 

Boston Scientific
Boston Scientific has established itself as a leading global player in airway stents, leveraging its long-standing expertise in interventional devices. Its strategy emphasizes innovation in drug-eluting designs and collaborations with pulmonology research centers . The company has also focused on expanding its footprint in Asia-Pacific through targeted partnerships, recognizing the region’s rising lung cancer and COPD burden.

 

Merit Medical Systems
Merit Medical is known for its diversified interventional portfolio, with a strong emphasis on affordability and procedural efficiency. In lung stents, the company highlights ease-of-use designs that streamline bronchoscopy workflows. Merit has also invested in training programs for pulmonologists in emerging markets, building loyalty through education and technical support rather than competing purely on price.

 

Cook Medical
Cook Medical has carved a solid position with silicone and hybrid stents. The company’s differentiation lies in patient-centric customization, offering sizes and configurations that cater to complex airway anatomies. Cook has also been an early mover in exploring bioresorbable solutions, conducting collaborations with academic research institutions in Europe.

 

Micro-Tech (Nanjing)
As a China-based company, Micro-Tech has rapidly grown its presence, particularly in the Asia-Pacific region. Its competitive strength lies in cost-effectiveness and regional accessibility. The company has expanded aggressively into both domestic and international markets by offering reliable, lower-cost alternatives that appeal to hospitals with constrained budgets.

 

Taewoong Medical
Headquartered in South Korea, Taewoong Medical is recognized for its innovation in self-expanding metallic stents. Its products are widely adopted across Asia and increasingly in Europe. The company is actively working on drug-eluting variants and aims to strengthen its foothold in North America through distribution partnerships.

 

Novatech SA
Novatech, a France-based player, has long specialized in silicone stents and holds strong brand recognition among European hospitals. Its focus has been on safety and biocompatibility, with stents often used in complex oncological cases. The company maintains close ties with thoracic surgery centers and continues to expand through incremental innovation rather than radical redesign.

 

Competitive Landscape at a Glance
The market is relatively concentrated, with a handful of companies dominating by region. Western players like Boston Scientific and Cook lead in advanced markets, while Asian companies like Micro-Tech and Taewoong are expanding globally by offering competitive pricing and local accessibility. Niche firms like Novatech maintain specialized strongholds. Increasingly, success will depend on partnerships — both with academic research centers to advance next-generation designs and with hospitals to build procedural ecosystems.

 

To be honest, this is not a volume-driven battle. Hospitals are unlikely to switch suppliers easily, given the high stakes of airway procedures. Trust, clinical validation, and training matter more than price — which is why companies that combine innovation with physician support are best positioned to sustain long-term leadership.

 

Regional Landscape And Adoption Outlook

Adoption of lung stents varies sharply across regions, influenced by healthcare infrastructure, disease prevalence, reimbursement policies, and access to advanced interventional pulmonology. While North America and Europe remain the technology and innovation hubs, Asia-Pacific is emerging as the growth engine due to its large patient pool and rising investments in healthcare.

North America
North America continues to be the largest market for lung stents, supported by well-established healthcare systems, a high prevalence of lung cancer and COPD, and early adoption of advanced interventional techniques. The U.S. leads the region, with widespread use of metallic and hybrid stents across cancer centers and tertiary hospitals. Reimbursement frameworks for airway management procedures further strengthen adoption. Canada is following a similar trajectory, though access disparities remain between major urban hospitals and smaller provincial facilities.

 

Europe
Europe is the second-largest market, characterized by standardized treatment guidelines and strong adoption of silicone stents, particularly in oncological care. France, Germany, and the UK are key countries, with Novatech maintaining a strong footprint in its domestic market. The region has also been active in research on bioresorbable and drug-eluting stents, driven by collaborations between medical device companies and academic hospitals. Eastern European countries, however, face slower adoption due to limited budgets and reliance on traditional metallic designs.

 

Asia-Pacific
Asia-Pacific is projected to be the fastest-growing region for lung stents between 2024 and 2030. Rising smoking prevalence, industrial pollution, and high rates of COPD and lung cancer make airway interventions increasingly necessary. China and India represent the largest opportunities, with rapid hospital expansion and government-led initiatives to strengthen cancer care infrastructure. South Korea and Japan are leading in innovation, with domestic companies like Taewoong actively exporting their products. However, disparities in access between urban hospitals and rural facilities remain a significant challenge, often addressed through lower-cost alternatives from local manufacturers.

 

Latin America
In Latin America, adoption is growing but remains uneven. Brazil and Mexico lead the way, supported by expanding private healthcare facilities and urban cancer centers . Public healthcare systems are gradually incorporating stents, but financial constraints continue to slow widespread adoption. Awareness among clinicians is improving, though training gaps in interventional pulmonology still limit penetration outside major cities.

 

Middle East and Africa
The Middle East and Africa remain underpenetrated markets, though select countries are investing heavily in advanced healthcare infrastructure. Saudi Arabia and the UAE are building specialized cancer centers that are beginning to incorporate advanced lung stent technologies. In Africa, adoption is minimal and largely dependent on NGO-supported programs or imported devices used in limited tertiary hospitals. Affordability remains the biggest barrier, with most patients still relying on symptomatic management rather than advanced interventions.

 

Key Regional Dynamics
North America and Europe will continue to drive innovation through regulatory approvals and academic research. Asia-Pacific will be the growth hotspot, providing both volume and new opportunities for lower-cost and next-generation stents. Latin America and the Middle East will offer selective high-value opportunities in urban hospitals, while Africa represents the long-term frontier where affordability and training will define eventual adoption.

 

The reality is that while technology is advancing rapidly, access is not equal. The regions that can combine innovation with affordability and clinical training will define the future shape of the global lung stent market.

 

End-User Dynamics And Use Case

End-user adoption of lung stents depends on the type of healthcare facility, the availability of trained specialists, and the complexity of cases treated. Each category of end user demonstrates different purchasing priorities and clinical workflows, which directly shape demand.

Hospitals
Large tertiary hospitals and cancer centers remain the primary users of lung stents. These institutions treat advanced-stage cancer and severe COPD cases that often require interventional pulmonology or thoracic surgery. Hospitals typically favor metallic, silicone, or hybrid stents depending on the patient’s condition and long-term prognosis. Many hospitals also act as research hubs, piloting bioresorbable and drug-eluting stents in collaboration with medical device companies.

 

Specialty Clinics
Pulmonology and thoracic surgery clinics are increasingly adopting lung stents, especially in urban areas with strong referral networks. Their emphasis is on quick and minimally invasive procedures, often for patients with localized airway strictures. Specialty clinics are also investing in advanced bronchoscopy systems that improve precision in stent placement, aligning with the trend toward outpatient-based care.

 

Ambulatory Surgical Centers (ASCs)
ASCs are a smaller but growing segment, particularly in developed markets where healthcare systems encourage cost-efficient care outside hospitals. Their use of lung stents is typically limited to straightforward cases such as benign airway strictures or selected COPD patients. They value devices that are easy to deploy, reduce procedure time, and minimize complications, since extended patient monitoring is not feasible in these settings.

 

Diagnostic and Imaging Centers
While not primary users of stents, diagnostic centers with interventional bronchoscopy capabilities are beginning to perform airway procedures in select markets. These centers cater to insured patients seeking faster access to treatment and play a growing role in outpatient stent placements, particularly in regions where hospital wait times are high.

 

Use Case Highlight
A leading cancer hospital in India faced a surge in late-stage lung cancer patients presenting with central airway obstruction. Many of these patients had limited access to palliative care and required immediate airway intervention to restore breathing. The hospital adopted a hybrid metallic-silicone stent system, allowing for both durability and removability when necessary. Paired with AI-guided bronchoscopy software, the hospital reduced stent misplacement rates by nearly 25% within the first year of use. Patients experienced faster symptom relief, fewer repeat interventions, and improved overall quality of life, while the hospital strengthened its reputation as a national referral center for advanced airway management.

 

End-user dynamics in this market reveal a clear divide: hospitals lead in volume and innovation, specialty clinics drive accessibility, and ASCs focus on efficiency. The stent manufacturers that can cater to each of these needs — without overcomplicating procedures — are the ones most likely to dominate adoption in the next five years.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

• Boston Scientific received FDA clearance in 2023 for an updated self-expanding metallic lung stent designed with improved anti-migration features.

• Merit Medical Systems partnered with a U.S. cancer center in 2024 to trial a drug-eluting airway stent incorporating anti-inflammatory coatings.

• Cook Medical expanded its hybrid silicone stent line in Europe in 2023, following CE approval for newer sizes intended for complex bronchial anatomies.

• Taewoong Medical launched a next-generation metallic stent with a proprietary delivery system in South Korea in late 2023, now entering export markets.

• Micro-Tech (Nanjing) established a manufacturing plant expansion in 2024 to meet rising domestic demand in China and to scale exports across Asia-Pacific.

 

Opportunities

• Precision Medicine Integration : As oncology treatment becomes more individualized, demand is rising for stents that can be tailored to patient-specific airway structures or incorporate localized drug delivery.

• Growth in Emerging Markets : Asia-Pacific, Latin America, and parts of the Middle East are expanding hospital infrastructure, creating new demand for affordable yet reliable stent solutions.

• Innovation in Bioresorbable Designs : The pipeline for biodegradable stents offers long-term opportunities to reduce complications and limit repeat procedures.

 

Restraints

• High Device Costs : Advanced stent technologies such as drug-eluting or bioresorbable models remain expensive, restricting access in lower-income regions.

• Limited Skilled Workforce : Many hospitals, especially in emerging markets, lack adequately trained pulmonologists or thoracic surgeons to perform complex stent placements.

• Complication Risks : Issues such as stent migration, infection, and granulation tissue remain persistent clinical challenges that slow broader adoption.

To be candid, the real ceiling for this market isn’t patient demand — it’s execution. Vendors that can lower costs, simplify procedures, and reduce complication risks will unlock much faster adoption worldwide.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 510 Million
Revenue Forecast in 2030	USD 800 Million
Overall Growth Rate	CAGR of 6.8% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Product Type, Indication, End User, Geography
By Product Type	Metallic Stents, Silicone Stents, Hybrid Stents, Bioresorbable Stents
By Indication	Lung Cancer, COPD, Tracheobronchial Strictures, Post-Surgical Cases
By End User	Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Diagnostics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, UK, France, China, India, Japan, Brazil, GCC
Market Drivers	- Rising prevalence of lung cancer and COPD - Advances in stent design (drug-eluting, bioresorbable) - Growing adoption of minimally invasive pulmonology
Customization Option	Available upon request